<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>jmedicalcasereports</PublisherName>
<JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Volume 5; Issue 5</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>(Sep-Oct, 2024)</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2024</Year>
<Month>09</Month>
<Day>24</Day>
</PubDate>
<ArticleType>Medical Case Reports</ArticleType>
<ArticleTitle>Emerging Therapeutic Approaches to Drug-Resistant Tuberculosis: A Case Report and Review of Novel Treatments</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>1</FirstPage>
<LastPage>5</LastPage>
<AuthorList>
<Author>
<FirstName>Ashish</FirstName>
<LastName>Pandey</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Drug-resistant tuberculosis (DR-TB), particularly multidrug-resistant tuberculosis (MDR-TB), poses a major global health challenge. Conventional treatment regimens are long, toxic, and often ineffective. This case report describes a 32-year-old male patient with MDR-TB unresponsive to standard therapies, successfully treated using a novel combination of repurposed drugs, immunomodulators, and bacteriophage therapy. Sputum cultures converted to negative within three months, with sustained clinical and radiological improvement over 12 months. The review further discusses the integration of artificial intelligence (AI) in optimizing treatment regimens, a promising but underexplored area in MDR-TB management. This case underscores the need for innovative therapeutic approaches to improve outcomes in DR-TB.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Multidrug-Resistant Tuberculosis,Repurposed Drugs,Immunomodulation,Phage Therapy,Artificial Intelligence,Drug Development,Tuberculosis Treatment</Keywords>
<URLs>
<Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=15377&title=Emerging Therapeutic Approaches to Drug-Resistant Tuberculosis: A Case Report and Review of Novel Treatments</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Abedon ST, Garcand;iacute;a P, Mullany P, Aminov R. Editorial: Phage Therapy: Past, Present and Future. Front Microbiol 2017;8: 981.
Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-54.
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, Gilmour KC, Soothill J, Jacobs-Sera D, Schooley RT, Hatfull GF, Spencer H. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med 2019; 25: 730-733.
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017; 15: S2213-2600(17)30079-6.
Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Coussens AK, Oni T, Warwick JM, Said-Hartley Q, Koegelenberg CF, Walzl G, Flynn JL, Young DB, Barry Iii CE, Oand;#39;Garra A, Wilkinson RJ. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F] fluoro-D-glucose positron emission and computed tomography. Nat Med 2016; 22: 1090-1093.
Hatfull GF, Dedrick RM, Schooley RT. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annu Rev Med 2022; 73: 197-211.
Keshavjee S, Gelmanova IY, Pasechnikov AD, Mishustin SP, Andreev YG, Yedilbayev A, Furin JJ, Mukherjee JS, Rich ML, Nardell EA, Farmer PE, Kim JY, Shin SS. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann N Y Acad Sci 2008; 1136: 1-11.
Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE 3rd. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
Sotgiu G, Centis R, Dand;#39;Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.</References>
</References>
</Journal>
</Article>
</ArticleSet>